Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized double-blind placebo-controlled multicenter Phase 3 study of efficacy and safety of AR-301 as adjunct therapy to antibiotics in the treatment of Ventilator-Associated Pneumonia (VAP) caused by S. aureus

Next Previous
Trial Profile

A Randomized double-blind placebo-controlled multicenter Phase 3 study of efficacy and safety of AR-301 as adjunct therapy to antibiotics in the treatment of Ventilator-Associated Pneumonia (VAP) caused by S. aureus

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tosatoxumab (Primary) ; Antibacterials
  • Indications Nosocomial pneumonia; Staphylococcal infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Aridis Pharmaceuticals

    • Most Recent Events

    • 13 Nov 2019 According to Aridis Pharmaceuticals media release, this trial presents the first ever Phase 3 superiority clinical study evaluating immunotherapy with a fully human monoclonal antibody to treat acute pneumonia in the intensive care unit setting.
    • 13 Nov 2019 According to an Aridis Pharmaceuticals media release, the company expects to announce top line data in early 2021.
    • 14 May 2019 According to an Aridis Pharmaceuticals media release, the Investigational New Drug (IND) application to include China among the patient enrolling countries in the study was accepted by the Chinese FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top